Farmaprojects | Polpharma Group

We've traveled to the future of healthcare 🛫 Last month, a team from Portfolio and MI visited Polpharma’s R&D Center in Warsaw. They are developing state-of-the-art complex injectables and differentiated ophthalmics for Polpharma Group's portfolio. Led by Katarzyna Malik, PhD, the team drives the growth of Polpharma's strategic assets in oligonucleotides. They are the brains behind our preservative-free ophthalmic products. R&D is not just an option for us. It’s central to our strategy. It fuels our ideas and drives innovation. The atmosphere at Polpharma was welcoming. We had inspiring talks about future plans and could feel the excitement about expanding our pipeline. 🟨 Strong R&D teams are vital to shape the future of B2B in the pharmaceutical industry. #YesYouHealth #Farmaprojects #Polpharma #B2BPharma #R&D

The oligonucleotide therapeutics market size is valued at 5.4 Bn € in 2023 and is predicted to reach 10.9 Bn € by 2033. Farmaprojects | Polpharma Group is at the forefront of the market. We are working to develop complex RNA-based generics in our 5 R&D centers from the Polpharma Group. 🟨 Discover more: https://lnkd.in/d-fMY7id #RNATherapeutics #B2BPharma #Portfolio #Farmaprojects

The oligonucleotide therapeutics market size is valued at 5.4 Bn € in 2023 and is predicted to reach 10.9 Bn € by 2033. Farmaprojects | Polpharma Group is at the forefront of the market. We are working to develop complex RNA-based generics in our 5 R&D centers from the Polpharma Group. 🟨 Discover more: https://lnkd.in/d-fMY7id #RNATherapeutics #B2BPharma #Portfolio #Farmaprojects

🚀 We broke a record! Our latest employee pulse survey shows an 83% satisfaction rate. This score, provided by an external and independent pulse check survey conducted by Mercer Poland, shows that our hard work is paying off. Digitalization, process improvement, corporate benefits, and training are key to positioning Farmaprojects | Polpharma Group above the benchmark. But the biggest win? It’s our focus on employee well-being. We are dedicated to making things even better. We celebrate this achievement, but we won't stop here. Our commitment to enhancing the employee experience continues until we reach 100%. We aim to provide everyone at Farmaprojects with: 🟨 The right tools: Empowering our team leads to success. 🟨 Supportive environment: A positive workplace fosters creativity. 🟨 Continuous growth: Learning opportunities keep us moving forward. Yes to growing together. Yes You Health.  #EmployeeExperience #Engagement #GreatPlacetoWork #Farmaprojects

🌍 Reinforcing partnerships in Iraq and Kurdistan. Wassim Altarche Xifró, PhD, PharmD., Key Account Manager, attended EIF Erbil International Fair (MEDICO), a prominent international health exhibition in Iraq and the Kurdistan region, held in Erbil, on the 5-8th of February. This event reinforces our commitment to providing high-quality medicines in the region. It was an excellent opportunity to represent Farmaprojects | Polpharma Group and Polpharma Group and showcase Polpharma’s pharmaceutical products marketed in Iraq. Thanks, Pure Pharma (ESB Group), our B2B distributor in the region, for the invitation. #MEDICO #Farmaprojects #PortfolioStrategy #PartnershipOpportunities

Don’t miss the opportunity!

Exciting update for the days ahead! 🔜 We’ll participate at BePharmaB2B taking place on the 31st of March and 1st of April 2025 in Mexico City. Roberto Asensio and Joan Castanyer Costa are eager to connect with local industry leaders and companies interested in partnering with us. We look forward to engaging with fellow professionals and discovering new opportunities in the field. Will we see you there? #Farmaprojects #BePharma2025 #B2BPharma

How to differentiate in an overcrowded generics market? It's been 40 years since the growth of the generic drug market was fueled in the U.S. The Hatch-Waxman Amendments allowed generic drug manufacturers to demonstrate bioequivalence through pharmacokinetic studies, avoiding clinical trials. 📈 In 1984 only 19% of all prescription drug purchases in the U.S. were generics. 📈 By 2004, this grew to more than 53%. 📈 Today, generic drugs account for more than 90% of prescriptions filled in the U.S. Generics are generics, which means no differentiation. When your product is the same, your service is key. ✅ Go further than simple product development. This means actively listening to and understanding your client's needs. We perform a good market analysis, study market share in our client's relevant markets, and analyze competitor pricing to provide solutions to our customers to improve their market share. We are an agile company backed by the manufacturing resources of the Polpharma Group. We are there for you. Check it out: https://lnkd.in/d9kquK8x #YesYouHealth #Farmaprojects #Polpharma #B2BPharma #R&D #Generics

Our sales team is now equipped with top-notch negotiation tactics and selling strategies. Francesc Aroca, negotiation and leadership expert from MRC International People Training, trained our team on effective selling and negotiation. Skills? Sharpened. Confidence? Boosted. Dedication? Unwavering. 🟨 Yes You Health is not just a tagline. It’s our commitment. With this training, we are more equipped to help everyone achieve their healthcare goals. From customers to patients, from partners to employees. #YesYouHealth #OneTeam #Farmaprojects #Polpharma #TeamCulture #Training #B2BPharma

We are attending #BioEuropeSpring in Milan! Hendrik M., Portfolio Manager, will join forces with Małgorzata Masłowska from Polpharma Group, Project Manager of our external development projects, to connect for innovation. 📍Allianz Milano Convention Centre, Milan 🗓️ 17-19th March Reach out to connect with us to explore new partnerships in differentiated generics, catch up on trends in drug-delivery technology, and how we can collaborate to enable innovation in the field. #BioEuropeSpring #Farmaprojects #PortfolioStrategy #PartnershipOpportunities